In the Gilger Laboratory, we study the pathogenesis of ocular immunologic and inflammatory disorders and have developed innovative methods to treat these potentially blinding diseases. We have been especially interested in two very common causes of blindness, recurrent uveitis (non-infectious uveitis) and fungal keratitis. We develop methods to deliver therapeutic levels of medications to the eye for extended periods of time using micro-implant and sustained release injection technology. Finally, we work extensively with the Gene Therapy Center at UNC-Chapel Hill and Dr. Matt's Hirsch Laboratory to study innovative gene therapies for corneal and other front-of-the eye diseases. https://gilgerlab.cvm.ncsu.edu

Bedrock’s scientific team brings together the disciplines of immunology, DNA repair, crystallography, and clinical sciences to conceive, engineer, and validate novel therapeutics as well as platform technologies for treatment of ocular disorders

Consultation for ocular toxicology, ocular surgery, implant development, and GLP studies

Assistant Professor in the College of Veterinary Medicine. Large and small animal ophthalmology